// App-Quantinova.ai

: Modeling Progression of CML Using Mutagenized Patient-Derived Induced Pluripotent Stem Cells (iPSCs): Potential Tool for Discovering Novel Therapeutic Targets

Researchers

Presenter

  • Jusuf Imeri

Principal Investigators

  • Christophe Desterke

  • Gladys Telliam

  • Paul Marcoux

  • Nathalie Sorel

  • Safa Sanekli

  • Sylvain Barreau

  • Yucel Erbilgin

  • Theodoros Latsis

  • Patricia Hugues

  • Emilie Cayssials

  • Jean Claude Chomel

  • Annelise Bennaceur Griscelli

  • Ali G Turhan

Medical Centers

  • CHU Poitiers, Poitiers, FRA

  • Poitiers University Hospital, Poitiers, France

  • Inserm U University Paris Sud, Villejuif, France

  • Inserm UMS , CITHERA Center for iPSC Therapies, Evry, France

  • INSERM U, Villejuif, France

  • Department of Hematology, Inserm U, Villejuif, France

  • I.U. Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey

  • Inserm U and University Paris Saclay, , FRA

Locations

  • France

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Hematological malignancies

  • Teratoma

  • Diffuse idiopathic skeletal hyperostosis

Biomarkers

  • Myeloperoxidase

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 25

  • Cluster of Differentiation 43

  • Cluster of Differentiation 34

  • Tumor protein p53

Drug/Treatment

  • L-Tyrosine

  • TP53

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved